Endogenous Glucagon-Like Peptide 1 Enhanced by Vildagliptin Reduces Triglyceride Appearance During Intraduodenal Fat Infusion in Type 2 Diabetes.

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

The researchers evaluated the effect of dipeptidyl peptidase 4 (DPP-4) inhibition on the response of plasma triglycerides (TGs) to intraduodenal lipid and a mixed meal, and the impact of GLP-1 receptor blockade with exendin(9-39) in T2D.

A lipid emulsion was infused intraduodenally (2 kcal/min, t = 0-120 min), followed by a mixed meal (t = 120-150 min).

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

In the crossover set-up each of the participants took both Glucagon and the comparison in turn, acting as their own control.

What Was Measured

The researchers evaluated the effect of dipeptidyl peptidase 4 (DPP-4) inhibition on the response of plasma triglycerides (TGs) to intraduodenal lipid and a mixed meal, and the impact of GLP-1 receptor blockade with exendin(9-39) in T2D.

The subject headings attached to it are Adamantane, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Duodenum, Glucagon-Like Peptide 1, Hypoglycemic Agents and Nitriles.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon.

The publication is from 2026 (Diabetes), a journal based in United States.

More context: the Glucagon compound page, all human trials.